Track topics on Twitter Track topics that are important to you
Immune checkpoint inhibitor drugs have added a dimension to physicians’ arsenal in their fight against cancer. However, not all patients will respond to the currently approved therapies, wasting precious time that could be spent using other potentially lifesaving drugs. Now, a team of investigators has developed an integrated genomic approach that potentially could help physicians predict which patients will respond to therapy with immune checkpoint inhibitors.
The post Multimodal Genomic Predictor of Immunotherapy Success appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Multimodal Genomic Predictor of Immunotherapy SuccessNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...